Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma

Testing of the MGMT promoter methylation status in glioblastoma is relevant for clinical decision making and research applications. Two recent and independent phase III therapy trials confirmed a prognostic and predictive value of the MGMT promoter methylation status in elderly glioblastoma patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Preusser, Matthias, Berghoff, Anna S., Manzl, Claudia, Filipits, Martin, Weinhäusel, Andreas, Pulverer, Walter, Dieckmann, Karin, Widhalm, Georg, Wöhrer, Adelheid, Knosp, Engelbert, Marosi, Christine, Hainfellner, Johannes A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891253/
https://www.ncbi.nlm.nih.gov/pubmed/24359605
http://dx.doi.org/10.5414/NP300730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891253/
https://www.ncbi.nlm.nih.gov/pubmed/24359605
http://dx.doi.org/10.5414/NP300730

Ejemplares similares